Domantis is a drug discovery company, which is exploiting its proprietary dominance in Domain Antibodies (dAbs) to deliver human therapies that address large, unmet medical needs including inflammation (e.g. rheumatoid arthritis), cancer (hematological and solid tumours) and autoimmune disease.

Fully human dAbs combine the best attributes of small molecule drugs (formulation and delivery versatility, broad target range and low costs) with those of full antibodies (enormous diversity, high specificity, lower toxicity). Thus, they have very broad therapeutic relevance

Domantis has extensive intellectual property covering libraries, methods of discovery, compositions, and formulations of dAbs and, as a result, is the only company capable of fully exploiting the commercial applications of dAbs from any species.